Elrexfio market seen growing on rising myeloma cases and oncology spending

The Business Research Company says the Elrexfio market is set for growth through 2035, driven by rising multiple myeloma cases, higher healthcare spending and expanding use of immunotherapies. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - The Elrexfio market is tied to broader demand for advanced cancer treatments, especially in blood cancers such as multiple myeloma and non-Hodgkin lymphoma. - Growth in this market can signal wider adoption of bispecific antibodies and other targeted immuno-oncology therapies. - Rising disease burden and higher health budgets may expand access to newer oncology drugs.

What happened: - The Business Research Company published its Elrexfio Global Market Report 2026 covering market size, trends and forecasts for 2026-2035. - The report says North America held the largest share of the Elrexfio market in 2025. - The report says Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The company offers a free sample of the report. - The company also offers the full report.

The details: - Elrexfio is the brand name for epcoritamab, a monoclonal antibody used for relapsed or refractory B-cell malignancies, including diffuse large B-cell lymphoma. - The drug targets CD3 on T-cells and CD20 on B-cells to help the immune system kill malignant B-cells. - The report identifies multiple myeloma as a major driver of market growth. - Elrexfio, also known as elranatamab in the release, treats multiple myeloma by targeting BCMA on myeloma cells. - The report cites Cancer Research UK projections showing new myeloma cases in the UK rising from about 6,800 a year in 2023-2025 to about 8,300 a year by 2038-2040. - The report says rising healthcare spending is supporting adoption of advanced oncology drugs. - Statistics Netherlands reported that Dutch healthcare spending reached about $130.70 billion in 2024, up 8.1% or $9.79 billion from 2023. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, and updated trend analysis.

Between the lines: - The report’s outlook suggests investors and drugmakers are watching not just current sales but the longer-term shift toward targeted and immune-based cancer therapies. - The emphasis on refractory lymphomas and precision oncology points to a market shaped by unmet medical need, not just broader oncology demand. - The inclusion of regional data and strategic tools suggests the report is aimed at both commercial planning and competitive benchmarking.

What's next: - The report expects broader use of immunotherapies, expanded indications, precision oncology advances and more biologic-drug investment to support growth through 2035. - Key trends expected to shape the market include bispecific antibodies, immuno-oncology expansion, targeted cancer therapies and T-cell engaging treatments. - North America is likely to remain a major market, while Asia-Pacific may gain share as healthcare investment and access to novel therapies increase.

The bottom line: - Elrexfio sits in a fast-growing corner of oncology where rising myeloma cases, better diagnostics and more spending on advanced therapies are likely to keep demand climbing.